Central Pain Syndrome Market

Market Overview:

The 7 major central pain syndrome markets reached a value of US$ 5.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.

The central pain syndrome market has been comprehensively analyzed in IMARC's new report titled "Central Pain Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Central pain syndrome is a neurological disorder characterized by persistent and debilitating pain that results from damage or dysfunction within the central nervous system. The pain associated with this condition is often described as a constant burning, aching, or stabbing sensation, and it may be localized to specific areas or affect larger regions of the body. Individuals suffering from the disorder may experience muscle stiffness, tingling, weakness, numbness, etc. This symptom can have a significant impact on a patient's quality of life, causing physical and emotional distress, sleep disturbances, depression, and anxiety. The diagnosis of central pain syndrome can be challenging, as there are no specific tests that can definitively confirm the disease. A healthcare professional will initially perform a thorough evaluation of clinical features and medical history, along with a comprehensive neurological examination. Additionally, numerous other imaging tests, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are utilized to identify structural abnormalities or lesions in the brain that could be contributing to the pain.

The rising cases of stroke, which can disrupt the blood flow to the brain, resulting in tissue damage, are primarily driving the central pain syndrome market. In addition to this, the increasing incidences of various associated risk factors, including trauma, infection, chronic stress, obesity, depression, etc., are also propelling the market growth. Furthermore, the widespread adoption of effective drugs, such as antidepressants, anticonvulsants, opioids, etc., to alleviate the pain and manage other symptoms related to the ailment is creating a positive outlook for the market. Besides this, the escalating popularity of non-pharmacological interventions, like physical and occupational therapies, that aim to improve daily functioning and promote independence in patients is also bolstering the market growth. Additionally, the emerging application of transcutaneous electrical nerve stimulation techniques, since they work by activating the nerves and interfering with pain signals, is acting as another significant growth-inducing factor. Moreover, the inflating demand for intrathecal drug delivery systems, owing to their numerous benefits over other oral or systemic medications, such as reduced side effects as well as enhanced convenience and compliance, is expected to drive the central pain syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the central pain syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for central pain syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the central pain syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the central pain syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the central pain syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current central pain syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the central pain syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the central pain syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the central pain syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of central pain syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of central pain syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of central pain syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with central pain syndrome across the seven major markets?
• What is the size of the central pain syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of central pain syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Central Pain Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for central pain syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the central pain syndrome market?
• What are the key regulatory events related to the central pain syndrome market?
• What is the structure of clinical trial landscape by status related to the central pain syndrome market?
• What is the structure of clinical trial landscape by phase related to the central pain syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the central pain syndrome market?